


Attorney Docket No. PC8835E
Application No. 09/820,158

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of a compound of the formula I:



wherein:

A is selected from CH₂ and NR;

B, D and E are independently selected from CH and N;

Y is

- (a) phenyl, optionally substituted with 1-3 substituents independently selected from R⁴;
- (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R⁴;
- (c) C₃-C₈ cycloalkyl, optionally substituted with 1-2 substituents independently selected from R⁴; or
- (d) C₃-C₈ cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R⁴;
- ~~(e) a five-membered heterocycle containing up to two heteroatoms selected from the group consisting of O, NR² and S(O)_n, optionally substituted with 1-3 substituents independently selected from R⁴;~~
- ~~(f) a six-membered heterocycle containing up to two heteroatoms selected from the group consisting of O, NR² and S(O)_n, optionally substituted with 1-3 substituents independently selected from R⁴; or~~


Attorney Docket No. PC8835E
Application No. 09/820,158

~~(g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of O, NR², NR² and S(O)_n, optionally substituted with 1-3 substituents independently selected from R⁴;~~

Z¹ is


- ~~(a) (CH₂)_pW(CH₂)_q;~~
- ~~(b) (a) -O(CH₂)_pCR⁵R⁶;~~
- ~~(c) (b) -O(CH₂)_pW(CH₂)_q; or~~
- ~~(d) (c) -OCHR²CHR³;~~ or
- ~~(e) -SCHR²CHR³;~~

G is



~~(a) -NR²R⁸;~~

~~(b)~~




~~wherein n is 0, 1 or 2; m is 1, 2 or 3; Z² is NH, O, S, or CH₂; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R⁴; or~~

~~(c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R⁴;~~

~~Z² and G in combination may be~~

Attorney Docket No. PC8835E
Application No. 09/820,158




W is

- (a) $-\text{CH}_2-$;
- (b) $-\text{CH}=\text{CH}-$;
- (c) $-\text{O}-$;
- (d) $-\text{NR}^2-$;
- (e) $-\text{S}(\text{O})_n-$;
- (f)



- (g) $-\text{CR}^2(\text{OH})-$;
- (h) $-\text{CONR}^2-$;
- (i) $-\text{NR}^2\text{CO}-$;
- (j)



- (k) $-\text{C}\equiv\text{C}-$;

R is hydrogen or C_1 - C_6 alkyl;

R^2 and R^3 are independently

- (a) hydrogen; or
- (b) C_1 - C_4 alkyl;

R^4 is

- (a) hydrogen;
- (b) halogen;
- (c) C_1 - C_6 alkyl;
- (d) C_1 - C_4 alkoxy;
- (e) C_1 - C_4 acyloxy;
- (f) C_1 - C_4 alkylthio;
- (g) C_1 - C_4 alkylsulfinyl;
- (h) C_1 - C_4 alkylsulfonyl;

Attorney Docket No. PC8835E
Application No. 09/820,158

- (i) hydroxy (C₁-C₄)alkyl;
- (j) aryl (C₁-C₄)alkyl;
- (k) -CO₂H;
- (l) -CN;
- (m) -CONHOR;
- (n) -SO₂NHR;
- (o) -NH₂;
- (p) C₁-C₄ alkylamino;
- (q) C₁-C₄ dialkylamino;
- (r) -NHSO₂R;
- (s) -NO₂;
- (t) -aryl; or
- (u) -OH.

R⁵ and R⁶ are independently C₁-C₈ alkyl or together form a C₃-C₁₀ carbocyclic

ring;

~~R⁷ and R⁸ are independently~~

- ~~(a) phenyl;~~
- ~~(b) a C₃-C₁₀ carbocyclic ring, saturated or unsaturated;~~
- ~~(c) a C₃-C₁₀ heterocyclic ring containing up to two heteroatoms, selected from O, N and S;~~
- ~~(d) H;~~
- ~~(e) C₁-C₈ alkyl; or~~
- ~~(f) form a 3 to 8 membered nitrogen containing ring with R⁵ or R⁶;~~

~~R⁷ and R⁸ in either linear or ring form may optionally be substituted with up to three substituents independently selected from C₁-C₈ alkyl, halogen, alkoxy, hydroxy and carboxy;~~

~~a ring formed by R⁷ and R⁸ may be optionally fused to a phenyl ring;~~

e is 0, 1 or 2;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 0, 1, 2 or 3;


q is 0, 1, 2 or 3;

~~and optical and geometric isomers thereof; and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, and quaternary ammonium salts thereof~~

Attorney Docket No. PC8835E
Application No. 09/820,158

or an optical or geometric isomer thereof; or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester or quaternary ammonium salt thereof.

2. (currently amended) A The method of claim 1 wherein the compound is a compound of the formula:



3. (original) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester, or quaternary ammonium salt thereof.

4. (original) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of *Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or an optical or geometric isomer thereof; or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester, or quaternary ammonium salt thereof.

5. (new) The method of claim 3 wherein (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is administered to the mammal.

6. (new) The method of claim 3 wherein the mammal is a human.

Attorney Docket No. PC8835E
Application No. 09/820,158

7. (new) The method of claim 6 wherein the human is female.

8. (new) The method of claim 5 wherein the amount of (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.1 mg to 50 mg administered to the mammal once to four times a day.

9. (new) The method of claim 8 wherein the amount of (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.25 mg to 25 mg administered to the mammal once to four times a day.

10. (new) The method of claim 9 wherein the (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is administered to the mammal once a day.

11. (new) The method of claim 10 wherein the mammal is human.

12. (new) The method of claim 11 wherein the human is female.